Crossmark Global Holdings Inc. Sells 18,306 Shares of Qiagen (NYSE:QGEN)

Crossmark Global Holdings Inc. lowered its position in shares of Qiagen (NYSE:QGEN) by 32.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 38,469 shares of the company’s stock after selling 18,306 shares during the period. Crossmark Global Holdings Inc.’s holdings in Qiagen were worth $1,713,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its stake in Qiagen by 77.7% during the third quarter. Wellington Management Group LLP now owns 21,250,943 shares of the company’s stock worth $963,386,000 after purchasing an additional 9,293,040 shares during the last quarter. Earnest Partners LLC lifted its stake in shares of Qiagen by 11.1% in the 2nd quarter. Earnest Partners LLC now owns 3,807,284 shares of the company’s stock valued at $156,441,000 after acquiring an additional 379,679 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of Qiagen by 62.6% in the 3rd quarter. Victory Capital Management Inc. now owns 2,574,705 shares of the company’s stock valued at $117,329,000 after acquiring an additional 991,325 shares during the last quarter. State Street Corp lifted its stake in shares of Qiagen by 3.9% in the 3rd quarter. State Street Corp now owns 2,380,008 shares of the company’s stock valued at $108,457,000 after acquiring an additional 90,181 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Qiagen by 16.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,320,088 shares of the company’s stock valued at $105,726,000 after acquiring an additional 324,417 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Trading Down 2.9 %

QGEN opened at $45.86 on Friday. The business has a 50 day simple moving average of $44.43 and a two-hundred day simple moving average of $44.22. The firm has a market capitalization of $10.47 billion, a price-to-earnings ratio of 117.59, a PEG ratio of 3.51 and a beta of 0.37. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89. Qiagen has a one year low of $39.03 and a one year high of $47.93.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Jefferies Financial Group reissued a “buy” rating and issued a $54.00 target price (up previously from $42.00) on shares of Qiagen in a research note on Tuesday, December 10th. Hsbc Global Res raised Qiagen to a “hold” rating in a research note on Thursday, October 17th. Morgan Stanley reissued an “equal weight” rating and issued a $48.00 target price (down previously from $50.00) on shares of Qiagen in a research note on Monday, January 6th. Finally, HSBC lowered Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price for the company. in a research note on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $51.50.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.